Background Major depressive disorder is estimated by the WHO to affect more than 300
million people globally, making depression the leading cause of disability worldwide …

Depression is widely acknowledged to be a heterogeneous entity, and the need to further
characterize the individual patient who has received this diagnosis in order to personalize …

Objectives To characterize individual participant level response distributions to acute
monotherapy for major depressive disorder in randomized, placebo controlled trials …

Major depressive disorder (MDD) is a common and severe mental disorder that is usually
recurrent and has a high risk of suicide. This disorder manifests not only with psychological …

Importance Depression is common and associated with substantial burden. Suicide rates
have increased over the past decade, and both suicide attempts and deaths have …

The issue of the severity of psychiatric disorders has great clinical importance. For example,
severity influences decisions about level of care, and affects decisions to seek government …

Background Depression is usually managed in primary care, but most antidepressant trials
are of patients from secondary care mental health services, with eligibility criteria based on …

The efficacy of antidepressants in the acute treatment of moderate-to-severe depression
remains a controversial issue. The minimal important difference (MID) is relevant to judge …

Background Evidence-based treatments for adult depression include psychotherapy and
pharmacotherapy, yet little is known about how baseline depression severity moderates …

Background Reports claiming that antidepressants are effective only in patients with severe
depression have affected treatment guidelines but these reports usually use a disputed …